Literature DB >> 3537101

Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves' disease.

G Robuschi, A Manfredi, M Salvi, E Gardini, M Montermini, L d'Amato, E Borciani, L Negrotti, A Gnudi, E Roti.   

Abstract

Graves' hyperthyroid patients were treated daily for 10 days with 1 g sodium ipodate, a cholecystographic agent which exerts a blocking effect on the peripheral conversion of T4 to T3, or with 12 drops of saturated solution of potassium iodide (SSKI). Serum concentrations of free T4 (FT4) and free T3 (FT3) were measured before, during and 5 and 10 days after the administration of each drug. Sodium ipodate treatment induced a rapid decrement of serum FT4 concentrations which declined from 48.9 +/- 6.6 pg/ml to 26.0 +/- 2.7 pg/ml. In these patients serum FT3 concentrations declined from 12.4 +/- 2.0 pg/ml to 2.5 +/- 0.4 pg/ml. Ten days after sodium ipodate withdrawal, serum FT4 and FT3 concentrations returned to baseline values. In patients treated with SSKI serum FT4 concentrations declined from 51.1 +/- 8.8 pg/ml to 11.3 +/- 1.4 pg/ml and FT3 from 15.7 +/- 2 pg/ml to 2.6 +/- 0.3 pg/ml. Moreover, after therapy interruption serum free thyroid hormone concentrations returned to baseline values in these patients. Serum FT4 pattern during the study was not different between the two groups of subjects whereas serum FT3 concentrations were significantly lower in patients treated with sodium ipodate. These findings indicate that SSKI and sodium ipodate are effective in inducing a rapid decrement of serum free thyroid hormone concentrations. Therefore the employment of these drugs may be useful in the treatment of patients with thyroid storm and those undergoing thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3537101     DOI: 10.1007/BF03346928

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Iodothyronine metabolism in rat liver homogenates.

Authors:  M M Kaplan; R D Utiger
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

2.  Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis.

Authors:  L Wartofsky; B J Ransil; S H Ingbar
Journal:  J Clin Invest       Date:  1970-01       Impact factor: 14.808

3.  Changes of circulating thyroxine, triiodothyronine and reverse triiodothyronine after radiographic contrast agents.

Authors:  H Bürgi; C Wimpfheimer; A Burger; W Zaunbauer; H Rösler; T Lemarchand-Béraud
Journal:  J Clin Endocrinol Metab       Date:  1976-12       Impact factor: 5.958

4.  The effects of iopodate on the serum iodothyronine pattern in normal subjects.

Authors:  C G Beng; M L Wellby; R G Symons; S Stuart; J Marshall
Journal:  Acta Endocrinol (Copenh)       Date:  1980-02

5.  Iodothyronine and thyrotropin concentrations after iodoamide administration for angiographic studies.

Authors:  R Emanuele; G Robuschi; A Tagliaferri; L D'Amato; M Salvi; A Gnudi; A Manfredi; T Tecchio; E Roti
Journal:  Ric Clin Lab       Date:  1982 Oct-Dec

6.  Comparative effects of sodium ipodate and iodide on serum thyroid hormone concentrations in patients with Graves' disease.

Authors:  E Roti; G Robuschi; A Manfredi; L D'Amato; E Gardini; M Salvi; M Montermini; A L Barlli; A Gnudi; L E Braverman
Journal:  Clin Endocrinol (Oxf)       Date:  1985-04       Impact factor: 3.478

7.  Inhibition of hepatic binding of thyroxine by cholecystographic agents.

Authors:  J V Felicetta; W L Green; W B Nelp
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

8.  Cardiac catheterization dye does not affect serum thyroid hormone concentrations or TSH secretion.

Authors:  R E Kleinmann; E Sternthal; O Starobin; L E Braverman
Journal:  Cathet Cardiovasc Diagn       Date:  1982

9.  The effect of repeated administration of ipodate (Oragrafin) in hyperthyroidism.

Authors:  S Y Wu; I J Chopra; D H Solomon; D E Johnson
Journal:  J Clin Endocrinol Metab       Date:  1978-12       Impact factor: 5.958

10.  Comparison sodium ipodate (oragrafin) and propylthiouracil in early treatment of hyperthyroidism.

Authors:  S Y Wu; T P Shyh; I J Chopra; D H Solomon; H W Huang; P C Chu
Journal:  J Clin Endocrinol Metab       Date:  1982-03       Impact factor: 5.958

View more
  3 in total

1.  Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.

Authors:  E Martino; S Balzano; L Bartalena; A Loviselli; V Sica; L Petrini; L Grasso; M Piga; L E Braverman
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

2.  Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy.

Authors:  F Bogazzi; F Aghini-Lombardi; C Cosci; I Lupi; F Santini; M L Tanda; P Miccoli; F Basolo; A Pinchera; L Bartalena; L E Braverman; E Martino
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

3.  Therapeutic effectiveness of potassium iodine in drug-naïve patients with Graves' disease: a single-center experience.

Authors:  Toyoyoshi Uchida; Hiromasa Goto; Takatoshi Kasai; Koji Komiya; Kageumi Takeno; Hiroko Abe; Nayumi Shigihara; Junko Sato; Akira Honda; Tomoya Mita; Akio Kanazawa; Yoshio Fujitani; Hirotaka Watada
Journal:  Endocrine       Date:  2014-02-04       Impact factor: 3.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.